{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:38:46Z","timestamp":1786117126567,"version":"build-2736575974"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Pers. Med.","JPM"],"abstract":"<jats:p>Vitiligo is an autoimmune depigmenting disorder characterized by marked heterogeneity in therapeutic response, both between patients and among lesions within the same individual. While current therapies primarily target interferon-\u03b3 (IFN-\u03b3)-driven inflammation, clinical outcomes remain variable and frequently incomplete, suggesting that additional lesion-specific biological factors contribute to repigmentation potential. In this narrative review, we propose the concept of repigmentation competence to describe the capacity of an individual lesion to achieve clinically meaningful repigmentation under therapy. We hypothesize that this competence emerges from the interaction of four interconnected biological axes: (i) cytokine network and immune memory, (ii) local immune regulation, (iii) regenerative capacity, and (iv) microenvironmental permissiveness. A targeted search of PubMed\/MEDLINE and ClinicalTrials.gov up to March 2026 was conducted to identify translational studies, mechanistic models, and clinical trials relevant to these pathways. Evidence was synthesized thematically with emphasis on cytokine-mediated mechanisms and their interaction with regenerative and tissue-context processes. The IFN-\u03b3\/CXCL9\/CXCL10 axis and tissue-resident memory T cells (TRM) represent the most clinically validated drivers of disease persistence, as demonstrated by the therapeutic efficacy of JAK inhibitors, although immune suppression alone often fails to achieve complete or durable repigmentation. In contrast, regulatory pathways involving PD-1\/PD-L1 signaling, regulatory T cells (Tregs), IL-10, TGF-\u03b2, and IL-2\u2013based strategies remain biologically compelling but only partially translated into effective therapies. Regenerative capacity has also emerged as an important determinant of treatment response, with growing evidence supporting the role of melanocyte stem cell niches, follicular regeneration, and Wnt\/\u03b2-catenin signaling. Accordingly, regenerative approaches such as non-cultured epidermal cell suspension (NCES) are increasingly being integrated into combination therapeutic strategies. The lesional microenvironment remains the least therapeutically developed axis despite growing experimental evidence supporting its importance in melanocyte survival and migration. Collectively, these observations suggest that the variable efficacy of current therapies may reflect different combinations of lesion-specific biological constraints. The emerging benefit of combination strategies may therefore derive not simply from additive effects, but from the simultaneous engagement of multiple axes involved in repigmentation competence. Our review supports a shift from a predominantly drug-centered model toward a lesion-oriented framework integrating immune, regenerative, regulatory, and microenvironmental determinants of response.<\/jats:p>","DOI":"10.3390\/jpm16080418","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:27Z","timestamp":1786021407000},"page":"418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-7617","authenticated-orcid":false,"given":"Maria Efenesia","family":"Baffa","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8290-638X","authenticated-orcid":false,"given":"Stefano","family":"Colabrese","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-8228","authenticated-orcid":false,"given":"Carlo","family":"Pipit\u00f2","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6014-7102","authenticated-orcid":false,"given":"Vincenzina","family":"Rubino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Visinoni","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Cerchiai","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7471-3471","authenticated-orcid":false,"given":"Marzia","family":"Caproni","sequence":"additional","affiliation":[{"name":"Rare Disease Dermatological Unit, Department of Health Sciences, Section of Dermatology, University of Florence, P. Palagi Hospital, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-4433","authenticated-orcid":false,"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12369","article-title":"Cellular stress and innate inflammation in organ-specific autoimmunity: Lessons learned from vitiligo","volume":"269","author":"Harris","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ref_7","unstructured":"(2026, July 23). A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream with Phototherapy in Participants with Vitiligo, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05247489."},{"key":"ref_8","unstructured":"(2026, July 23). A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants with Genital Vitiligo, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05750823."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15593258221105370","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamadermatol.2024.5737","article-title":"Combination of baricitinib and phototherapy in adults with active vitiligo: A randomized clinical trial","volume":"161","author":"Seneschal","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/idoj.IDOJ_474_18","article-title":"Oral tofacitinib: Contemporary appraisal of its role in dermatology","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: A phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_13","unstructured":"(2026, July 23). A Study to Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants with Vitiligo (Viti-Up), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06118411."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","unstructured":"(2026, July 23). A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo (Tranquillo) , Available online: https:\/\/clinicaltrials.gov\/study\/NCT05583526."},{"key":"ref_16","unstructured":"(2026, July 23). A Study to Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients with Vitiligo, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04774809."},{"key":"ref_17","unstructured":"(2026, July 23). A Phase II Study of the Efficacy and Safety of VC005 Tablets in Subjects with Non-Segmental Vitiligo, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07172347."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/ijd.70049","article-title":"Effectiveness and safety of ruxolitinib cream 15 mg\/g in patients with non-segmental vitiligo: A real-life study","volume":"65","author":"Cristallo","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lili, Y., Yi, W., Ji, Y., Yue, S., Weimin, S., and Ming, L. (2012). Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037513"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1111\/pcmr.70067","article-title":"PD-1\/PD-L1 Checkpoint Dysfunction in Vitiligo: Novel Pathogenic Insights and Therapeutic Innovation","volume":"38","author":"Ahmed","year":"2025","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/1523-1747.ep12480997","article-title":"Role of hair follicles in the repigmentation of vitiligo","volume":"97","author":"Cui","year":"1991","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/416854a","article-title":"Dominant role of the niche in melanocyte stem-cell fate determination","volume":"416","author":"Nishimura","year":"2002","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jid.2017.09.040","article-title":"Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the \u03b2-Catenin Pathway in the Hair Follicle Bulge Stem Cells","volume":"138","author":"Goldstein","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s10020-025-01236-z","article-title":"Comprehensive single-cell transcriptomic reveals different destinies of melanocytes and dynamic changes of immune microenvironment in a psychological stress-induced leukoderma and leukotrichia mouse model","volume":"31","author":"Cao","year":"2025","journal-title":"Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaad.2024.08.027","article-title":"Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation","volume":"91","author":"Hamzavi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/jid.2015.25","article-title":"Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo","volume":"135","author":"Wagner","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","article-title":"A critical appraisal of vitiligo etiologic theories: Is melanocytorrhagy the predominant mechanism?","volume":"16","author":"Gauthier","year":"2003","journal-title":"Pigment Cell Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Komatsu, T., Dong, Y., Ikeda, T., and Kawakami, T. (2025). Linking IFN-\u03b3-mediated pathogenesis to ROCK-targeted therapy in a scalable iPSC-based vitiligo model. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26168069"},{"key":"ref_34","unstructured":"(2026, July 23). A Study to Evaluate AMG 714 for Vitiligo (REVEAL), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04338581."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yang, P., Luan, M., Li, W., Niu, M., He, Q., Zhao, Y., Chen, J., Mao, B., Mou, K., and Li, P. (2023). Single-cell transcriptomics reveals peripheral immune responses in non-segmental vitiligo. Front Immunol., 14.","DOI":"10.3389\/fimmu.2023.1221260"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/ijd.17959","article-title":"Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives","volume":"64","author":"Lerner","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo with Tumor Response in Patients with Metastatic Melanoma Treated with Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Willemsen, M., Melief, C.J.M., Bekkenk, M.W., and Luiten, R.M. (2020). Targeting the PD-1\/PD-L1 Axis in Human Vitiligo. Front Immunol., 11.","DOI":"10.3389\/fimmu.2020.579022"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjd.12377","article-title":"Association between FOXP3 polymorphisms and vitiligo in a Han Chinese population","volume":"169","author":"Song","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun."},{"key":"ref_44","unstructured":"(2026, July 23). A Clinical Study of MK-6194 for the Treatment of Vitiligo. ClinicalTrials.gov. NCT06113328, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06113328."},{"key":"ref_45","unstructured":"(2026, July 23). Open-Label Pilot Study of Abatacept for the Treatment of Vitiligo ClinicalTrials.gov Identifier: NCT02281058, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02281058?cond=vitiligo&intr=abatacept&viewType=Card&rank=1."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.jid.2022.09.054","article-title":"045 Melanocyte- Targeted Bispecific PD- 1 Agonists as Localized Immune Suppressants Against Vitiligo","volume":"142","author":"Bossi","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","unstructured":"(2026, July 23). A Study of Upadacitinib in Combination with Non-Cultured Epidermal Cell Suspension Transplantation in Vitiligo, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06454461."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/jid.2015.92","article-title":"A new view of vitiligo: Looking at normal-appearing skin","volume":"135","author":"Picardo","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.det.2016.11.015","article-title":"Repigmentation through melanocyte regeneration in vitiligo","volume":"35","author":"Birlea","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gene.2019.03.026","article-title":"CDH1 and DDR1 common variants confer risk to vitiligo and autoimmune comorbidities","volume":"700","author":"Amoli","year":"2019","journal-title":"Gene"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Chang, W.L., and Ko, C.H. (2023). The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications. Cells, 12.","DOI":"10.3390\/cells12060936"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3193670","DOI":"10.1155\/omcl\/3193670","article-title":"An Overview of the Biological Complexity of Vitiligo","volume":"2024","author":"Matarrese","year":"2024","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_53","unstructured":"(2026, July 23). Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04525157?intr=Afamelanotide&viewType=Card&rank=14&tab=results."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamadermatol.2014.4848","article-title":"Indications and limitations of afamelanotide for treating vitiligo","volume":"151","author":"Passeron","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00403-024-03182-y","article-title":"Ritlecitinib, a JAK3\/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo","volume":"316","author":"Yamaguchi","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: A randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","article-title":"Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients with Vitiligo","volume":"142","author":"Pandya","year":"2022","journal-title":"J. Investig. Dermatol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/8\/418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:10:27Z","timestamp":1786021827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/8\/418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jpm16080418"],"URL":"https:\/\/doi.org\/10.3390\/jpm16080418","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}